A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.

Launched by MURDOCH CHILDRENS RESEARCH INSTITUTE · Apr 20, 2024

Keywords

ClinConnect Summary

The PEGASUS trial is a research study aimed at understanding how certain medications are processed by the body in young patients with Hodgkin or Non-Hodgkin Lymphoma. Specifically, the study is looking at changes in metabolism, which is how the body breaks down and uses these medications. This trial will include children and young adults aged 6 to 25 who are newly diagnosed with either type of lymphoma. By examining how well these medications are accepted and how feasible the testing is, the researchers hope to gather information that can lead to more personalized medicine for young cancer patients in the future.

Participants in the trial will take specific probe medications during their regular hospital visits for lymphoma treatment, and their blood will be tested to measure how their bodies metabolize these drugs. To be eligible for the study, participants must be able to swallow the medications and provide consent. However, those with certain medical conditions or previous cancer treatments may not qualify. Although the trial is not yet recruiting participants, it aims to pave the way for future studies that could improve treatment options for young patients battling cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 6-25 years of age.
• • New diagnosis of Hodgkin Lymphoma or Non-Hodgkin Lymphoma.
• • Able to swallow and absorb oral or nasogastric tube (NGT) administration of probe drugs.
• • Able to provide written informed consent.
• Exclusion Criteria:
• • Failure to comply with inclusion criteria.
• • Has a known previous allergy to any of the probe medications (i.e., omeprazole or dextromethorphan).
• • Common Terminology Criteria for Adverse Events (CTCAE) Grade IV end organ dysfunction (i.e., hepatic, renal, gastrointestinal).
• • Had previous oncological treatment (not first cancer diagnosis).
• • Is a clinically unstable patient requiring intensive care admission in high-risk circumstances will not be considered eligible for consent.
• • Any patient requiring urgent initiation of anti-cancer treatment outside hours where a member of the study staff is unable to approach the parent/guardian or participant for consent prior to commencing anti-cancer therapy will be ineligible for consent.
• • Unable to provide written informed consent.